A novel assessment of whole-mount Gleason grading in prostate cancer to identify candidates for radical prostatectomy: a machine learning-based multiomics study.

Autor: Ning J; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Spielvogel CP; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Haberl D; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Trachtova K; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic., Stoiber S; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Rasul S; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Bystry V; Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic., Wasinger G; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Baltzer P; Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, 1090 Vienna, Austria., Gurnhofer E; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Timelthaler G; Center for Cancer Research, Medical University of Vienna, 1090 Vienna, Austria., Schlederer M; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Papp L; Center for Medical Physics and Biomedical Engineering, Vienna, Austria., Schachner H; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Helbich T; Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, 1090 Vienna, Austria., Hartenbach M; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Grubmüller B; Department of Urology, Medical University of Vienna, Vienna, Austria.; Working Group of Diagnostic Imaging in Urology, Austrian Society of Urology, Vienna, Austria., Shariat SF; Department of Urology, Medical University of Vienna, Vienna, Austria.; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.; Department of Urology, University of Texas Southwestern, Dallas, Texas.; Division of Medical Oncology, Department of Urology, Weill Medical College of Cornell University, New York, New York.; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Hacker M; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Haug A; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Kenner L; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria.; Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.; Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria.; Center for Biomarker Research in Medicine (CBmed), Graz, Styria, Austria.

Publikováno v: Theranostics [Theranostics] 2024 Aug 01; Vol. 14 (12), pp. 4570-4581. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).

Inhibition of beta-catenin shows therapeutic potential in head and neck squamous cell carcinoma in vitro.

Autor: Maier T; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Stoiber S; Department of Pathology, Medical University of Vienna, Vienna, Austria.; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria., Gurnhofer E; Department of Pathology, Medical University of Vienna, Vienna, Austria., Haas M; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Kenner L; Department of Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Unit of Laboratory Animal Pathology, University of Veterinary Medicine, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; CBmed GmbH-Center for Biomarker Research in Medicine, Graz, Austria. lukas.kenner@meduniwien.ac.at., Heiduschka G; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Kadletz-Wanke L; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Brkic FF; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.

Publikováno v: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2023 Jan; Vol. 280 (1), pp. 399-408. Date of Electronic Publication: 2022 Aug 24.

Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer.

Autor: Spielvogel CP; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria., Stoiber S; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria.; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria., Papp L; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria., Krajnc D; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria., Grahovac M; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria., Gurnhofer E; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria., Trachtova K; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.; Centre for Molecular Medicine, Central European Institute of Technology, Brno, Czech Republic., Bystry V; Centre for Molecular Medicine, Central European Institute of Technology, Brno, Czech Republic., Leisser A; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria., Jank B; Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Schnoell J; Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Kadletz L; Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Heiduschka G; Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria., Beyer T; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria., Hacker M; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria., Kenner L; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at., Haug AR; Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria.; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Jan; Vol. 50 (2), pp. 546-558. Date of Electronic Publication: 2022 Sep 26.

Targeting Wnt/Beta-Catenin Signaling in HPV-Positive Head and Neck Squamous Cell Carcinoma.

Autor: Brkic FF; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, 1090 Vienna, Austria., Stoiber S; Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria., Maier T; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, 1090 Vienna, Austria., Gurnhofer E; Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria., Kenner L; Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.; Christian Doppler Laboratory for Applied Metabolomics, 1090 Vienna, Austria.; Unit of Laboratory Animal Pathology, University of Veterinary Medicine, 1210 Vienna, Austria.; CBmed GmbH-Center for Biomarker Research in Medicine, 8010 Graz, Austria., Heiduschka G; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, 1090 Vienna, Austria., Kadletz-Wanke L; Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Vienna, 1090 Vienna, Austria.

Publikováno v: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2022 Mar 20; Vol. 15 (3). Date of Electronic Publication: 2022 Mar 20.

Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.

Autor: Liang HC; Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria.; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK., Costanza M; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Group Biology of Malignant Lymphomas, Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, and Experimental and Clinical Research Center (ECRC), a joint cooperation between the MDC and Charité, Berlin, Germany., Prutsch N; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Zimmerman MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gurnhofer E; Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Montes-Mojarro IA; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Institute of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany., Abraham BJ; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Prokoph N; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Stoiber S; Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria.; Christian Doppler Laboratory (CDL) for Applied Metabolomics, Medical University of Vienna, Vienna, Austria., Tangermann S; Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria., Lobello C; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic., Oppelt J; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic., Anagnostopoulos I; Institute of Pathology, University of Würzburg, Würzburg, Germany., Hielscher T; German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Heidelberg, Germany., Pervez S; Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan., Klapper W; Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany., Zammarchi F; ADC Therapeutics (UK) Limited, London, UK., Silva DA; Institute for Protein Design, University of Washington, Seattle, WA, USA.; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Division of Life Science, The Hong Kong University of Science and Technology, Kowloon, Hong Kong., Garcia KC; Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Baker D; Institute for Protein Design, University of Washington, Seattle, WA, USA.; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Janz M; Group Biology of Malignant Lymphomas, Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, and Experimental and Clinical Research Center (ECRC), a joint cooperation between the MDC and Charité, Berlin, Germany., Schleussner N; Group Biology of Malignant Lymphomas, Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany.; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, and Experimental and Clinical Research Center (ECRC), a joint cooperation between the MDC and Charité, Berlin, Germany., Fend F; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Institute of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany., Pospíšilová Š; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Janiková A; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Wallwitz J; Department of Pharmacology, Physiology and Microbiology, Division Pharmacology, Karl Landsteiner University of Health Sciences, Krems, Austria., Stoiber D; Department of Pharmacology, Physiology and Microbiology, Division Pharmacology, Karl Landsteiner University of Health Sciences, Krems, Austria., Simonitsch-Klupp I; Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria., Cerroni L; Department of Dermatology, Medical University of Graz, Graz, Austria., Pileri S; Division of Haematopathology, European Institute of Oncology IRCCS, Milan, Italy., de Leval L; Institute of Pathology, Lausanne University Hospital (CHUV) and Lausanne University, Lausanne, Switzerland., Sibon D; Hematology Department, Necker University Hospital, Assistance Publique-Hôpitaux de Paris, and Institut Necker-Enfants Malades, INSERM UMR1151 (Normal and pathological lymphoid differentiation), Université de Paris, Paris, France., Fataccioli V; Department of Pathology, Henri Mondor University Hospital, AP-HP, INSERM U955, University Paris East, Créteil, France., Gaulard P; Department of Pathology, Henri Mondor University Hospital, AP-HP, INSERM U955, University Paris East, Créteil, France., Assaf C; Department of Dermatology, HELIOS Hospital Krefeld, Krefeld, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany., Knörr F; Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Damm-Welk C; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Woessmann W; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Pediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Turner SD; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK.; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic., Look AT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Mathas S; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK. stephan.mathas@charite.de.; Group Biology of Malignant Lymphomas, Max-Delbrück-Center (MDC) for Molecular Medicine, Berlin, Germany. stephan.mathas@charite.de.; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, and Experimental and Clinical Research Center (ECRC), a joint cooperation between the MDC and Charité, Berlin, Germany. stephan.mathas@charite.de.; German Cancer Consortium (DKTK) German Cancer Research Center (DKFZ), Heidelberg, Germany. stephan.mathas@charite.de., Kenner L; Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK. lukas.kenner@meduniwien.ac.at.; Christian Doppler Laboratory (CDL) for Applied Metabolomics, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Center for Biomarker Research in Medicine (CBMed) Core Lab 2, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at., Merkel O; Department of Pathology, Unit of Experimental and Laboratory Animal Pathology, Medical University of Vienna, Vienna, Austria. olaf.merkel@meduniwien.ac.at.; European Research Initiative on ALK-Related Malignancies (ERIA), Suzanne Turner, Cambridge, UK. olaf.merkel@meduniwien.ac.at.

Publikováno v: Nature communications [Nat Commun] 2021 Sep 22; Vol. 12 (1), pp. 5577. Date of Electronic Publication: 2021 Sep 22.